Anti-myelin-associated glycoprotein neuropathy
AJ Steck, AK Stalder, S Renaud - Current opinion in neurology, 2006 - journals.lww.com
AJ Steck, AK Stalder, S Renaud
Current opinion in neurology, 2006•journals.lww.comTherapy in patients with anti-MAG neuropathy is directed at reducing the antibody
concentration, blocking the effector mechanisms and depleting the monoclonal B cells. The
recent availability of rituximab, a monoclonal antibody suppressing B-cell clones, which is
not myelosuppressive and does not cause secondary malignancies, allows for early
targeted intervention.
concentration, blocking the effector mechanisms and depleting the monoclonal B cells. The
recent availability of rituximab, a monoclonal antibody suppressing B-cell clones, which is
not myelosuppressive and does not cause secondary malignancies, allows for early
targeted intervention.
Summary
Therapy in patients with anti-MAG neuropathy is directed at reducing the antibody concentration, blocking the effector mechanisms and depleting the monoclonal B cells. The recent availability of rituximab, a monoclonal antibody suppressing B-cell clones, which is not myelosuppressive and does not cause secondary malignancies, allows for early targeted intervention.
Lippincott Williams & Wilkins